Mankind Pharma: Scheme of arrangement for amalgamation of Prolijune Lifescinces Private Limited (WOS) with Mankind Pharma…
Mankind Pharma (MANKIND) filed a disclosure titled "Scheme of arrangement for amalgamation of Prolijune Lifescinces Private Limited (WOS) with Mankind Pharma Limited". The company is valued at about ₹95,485 crore.
What happened
Mankind Pharma (MANKIND) filed a disclosure with the exchanges on 26 October 2026 at 03:24 PM titled "Scheme of arrangement for amalgamation of Prolijune Lifescinces Private Limited (WOS) with Mankind Pharma Limited".
Company snapshot
Mankind Pharma is a mid-cap company in the Healthcare sector, with a market value of about ₹95,485 crore.
The stock last traded at ₹2,312, against a 52-week range of ₹1,909.7–₹2,642 (12.5% below the high).
Before this filing the shares had moved −10.2% over the month and −13.3% over three months. Average daily turnover over the last 20 sessions was about ₹144 crore.
Promoters held 72.63% at the end of Q1 FY27, down 0.03% points from the previous quarter. Foreign institutions owned 9.45% and domestic institutions 15.39%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 3,570 | 438.3 | 10.62 |
| Q2 FY26 | 3,697 | 511.5 | 12.39 |
| Q3 FY26 | 3,567 | 408.8 | 9.9 |
| Q4 FY26 | 3,443 | 554.4 | 13.44 |
| Q1 FY27 | 4,031 | 574.1 | 13.76 |
What history shows
This is not the company's first m&a disclosure: BCEIE has 7 earlier filings of this kind on record since May 2026.
After those filings, the stock fell 1.1% on average the next trading day and was up 0.8% on average after five days (6 filings with price data).
Across 143 similar disclosures by other Healthcare companies, shares moved +0.7% on average the next day and +0.8% over five days; 58% of them rose the next day.
Market-wide, 2,147 m&a filings with an impact score of 50 or more saw an average next-day move of +0.3%, with 49% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 15 Oct 2026 | Press release titled "Mankind Pharma to Acquire Majority Stake in… | −4.0% | — |
| 15 Oct 2026 | Intimation regarding investment by the Company. | −4.0% | — |
| 26 Aug 2026 | M&A | −0.5% | −1.0% |
| 13 Aug 2026 | M&A | −1.0% | −0.8% |
| 11 Jul 2026 | M&A | +0.2% | +1.6% |
What to watch
- Regulatory approvals, completion of the deal and its effect on revenue and margins.
- 26 October 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- Mankind Pharma to acquire 70% in Belgian biotech firm for €48 million
- Mankind Pharma to acquire 70% stake in Armed Cell Therapeutics for EUR 48 million
- Mankind Pharma buys majority stake in Armed Cell Therapeutics for €48 M
- Mankind Pharma to Acquire 70% Stake in Armed Cell Therapeutics for Rs 511.4 Crore
- Mankind Pharma Enters CAR-T Therapy Market with Majority Stake in Armed Cell Therapeutics
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.